Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treatment, the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP, particularly posterior zone I...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Samir N, Klufas, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711562/
https://www.ncbi.nlm.nih.gov/pubmed/31693715
http://dx.doi.org/10.2147/EB.S189684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711562/
https://www.ncbi.nlm.nih.gov/pubmed/31693715
http://dx.doi.org/10.2147/EB.S189684

Ejemplares similares